On October 19, 2022, the Antitrust Division of the Department of Justice announced that seven directors resigned from five different US public company boards of directors following DOJ concerns that their roles violated...more
10/21/2022
/ Acquisitions ,
Anti-Competitive ,
Antitrust Division ,
Competition ,
Corporate Counsel ,
Corporate Entities ,
Department of Justice (DOJ) ,
Disclosure Requirements ,
Emerging Technology Companies ,
Enforcement Actions ,
Mergers ,
Private Equity Firms ,
Section 8 ,
Securities and Exchange Commission (SEC) ,
The Clayton Act
On Friday, July 9, 2021, President Biden signed Executive Order 14036, Promoting Competition in the American Economy, which includes—among 72 initiatives aimed at enhancing competition in the US—a directive encouraging the...more
Citing concerns about growing consolidation, reduced competition, and increasing prices, President Biden issued on July 9, 2021 a sweeping Executive Order containing 72 initiatives to address competition concerns in a number...more
The new Executive Order includes 72 initiatives instructing more than a dozen federal agencies to consider adopting rules intended to enhance competition.
A new Executive Order signed by President Biden includes 72...more
Competition regulators have shown their ability to act quickly and decisively in order to help allay the worst impacts of the coronavirus outbreak. Could these responses provide a template for achieving environmental and...more
9/22/2020
/ Collaboration ,
Competition ,
Competition Authorities ,
Consumers ,
Coronavirus/COVID-19 ,
Department of Justice (DOJ) ,
Environmental Policies ,
European Commission ,
Federal Trade Commission (FTC) ,
Germany ,
Grocery Stores ,
Health Care Providers ,
Netherlands ,
No-Action Letters ,
Operators of Essential Services ,
Public Safety ,
Sustainability ,
Treaty on the Functioning of the European Union (TFEU) ,
UK Competition and Markets Authority (CMA) ,
United Nations
On April 4, 2020, the Antitrust Division of the Department of Justice issued its first Business Review Letter under the DOJ-FTC joint expedited COVID-19 competitor collaboration review procedures, blessing several medical...more
4/23/2020
/ Absolute Immunity ,
Antitrust Division ,
Antitrust Provisions ,
Business Review Letters ,
Collaboration ,
Competition ,
Coronavirus/COVID-19 ,
Department of Justice (DOJ) ,
Federal Trade Commission (FTC) ,
Medical Devices ,
Medical Research ,
Medical Supplies ,
No-Action Letters ,
Personal Protective Equipment ,
Pharmaceutical Industry ,
Prescription Drugs